Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-183465
Filing Date
2026-04-28
Accepted
2026-04-28 06:50:13
Documents
16
Period of Report
2026-04-27

Document Format Files

Seq Description Document Type Size
1 DEF 14A cgem-20260427.htm   iXBRL DEF 14A 1115312
2 GRAPHIC img154183647_0.jpg GRAPHIC 31700
3 GRAPHIC img154183647_1.jpg GRAPHIC 31700
4 GRAPHIC img154183647_2.jpg GRAPHIC 1125602
5 GRAPHIC img154183647_3.jpg GRAPHIC 88625
  Complete submission text file 0001193125-26-183465.txt   5345930

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20260427.xsd EX-101.SCH 11973
19 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20260427_htm.xml XML 412601
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39856 | Film No.: 26903049
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)